Backes FJ - Search Results

1

Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.

Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ. Levine MD, et al. Among authors: backes fj. Gynecol Oncol. 2024 Mar;182:51-56. doi: 10.1016/j.ygyno.2023.12.008. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262238

2

Robotic trocar site small bowel evisceration after gynecologic cancer surgery.

Seamon LG, Backes F, Resnick K, Cohn DE. Seamon LG, et al. Obstet Gynecol. 2008 Aug;112(2 Pt 2):462-4. doi: 10.1097/AOG.0b013e3181719ba8. Obstet Gynecol. 2008. PMID: 18669765

3

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.

Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ. Richardson DL, et al. Among authors: backes fj. Gynecol Oncol. 2008 Dec;111(3):461-6. doi: 10.1016/j.ygyno.2008.08.011. Epub 2008 Sep 30. Gynecol Oncol. 2008. PMID: 18829088

4

Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.

Backes FJ, Leon ME, Ivanov I, Suarez A, Frankel WL, Hampel H, Fowler JM, Copeland LJ, O'Malley DM, Cohn DE. Backes FJ, et al. Gynecol Oncol. 2009 Sep;114(3):486-90. doi: 10.1016/j.ygyno.2009.05.026. Epub 2009 Jun 10. Gynecol Oncol. 2009. PMID: 19515405

5

Are prediction models for Lynch syndrome valid for probands with endometrial cancer?

Backes FJ, Hampel H, Backes KA, Vaccarello L, Lewandowski G, Bell JA, Reid GC, Copeland LJ, Fowler JM, Cohn DE. Backes FJ, et al. Among authors: backes ka. Fam Cancer. 2009;8(4):483-7. doi: 10.1007/s10689-009-9273-5. Epub 2009 Jul 30. Fam Cancer. 2009. PMID: 19642020

6

Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients.

Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE. Resnick K, et al. Obstet Gynecol. 2009 Sep;114(3):530-536. doi: 10.1097/AOG.0b013e3181b11ecc. Obstet Gynecol. 2009. PMID: 19701031

7

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM. Richardson DL, et al. Among authors: backes fj. Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10. Gynecol Oncol. 2010. PMID: 20382413

8

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. O'Malley DM, et al. Among authors: backes fj. Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18. Gynecol Oncol. 2011. PMID: 21315428

9

Lynch syndrome.

Backes FJ, Cohn DE. Backes FJ, et al. Clin Obstet Gynecol. 2011 Jun;54(2):199-214. doi: 10.1097/GRF.0b013e3182185a41. Clin Obstet Gynecol. 2011. PMID: 21508689 Review.

10

Endometrial cancer patients and compliance with genetic counseling: room for improvement.

Backes FJ, Mitchell E, Hampel H, Cohn DE. Backes FJ, et al. Gynecol Oncol. 2011 Dec;123(3):532-6. doi: 10.1016/j.ygyno.2011.09.002. Epub 2011 Oct 2. Gynecol Oncol. 2011. PMID: 21968342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page